Patent Invalidation Faces Its Biggest Test: Supreme Court To Decide IPR Standard
This article was originally published in The Pink Sheet Daily
Executive Summary
Cuozzo litigation features battle lines familiar from legislation that created inter partes reviews in the first place, with BIO contending the standard for assessing patent claims gives challengers multiple bites at the apple and generic and high-tech companies saying it weeds out weak patents.
You may also be interested in...
Despite Supreme Court Win, PTO Moves To Drop BRI Patent Claim Standard
US Patent and Trademark Office now agrees with patent owners that PTAB should use the same standard as district courts in determining the meaning of patent claim terms.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.